Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Sotorasib (Lumakras) for the treatment of adult patients with KRAS G12C-mutated local···【more】
Article source：Captain MedicineRelease date：2026-03-23Recommended：41
On January 17, 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the combination of Sotorasib (Lumakras) and Panitumumab (Vectibix) for the treatm···【more】
Article source：Captain MedicineRelease date：2026-03-23Recommended：44
KRAS mutations have long been considered a major challenge in cancer research, remaining difficult to target for many years. The launch of Sotorasib has changed this landscape, off···【more】
Article source：Captain MedicineRelease date：2026-03-23Recommended：41
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021 and was subsequently launched.I.···【more】
Article source：Captain MedicineRelease date：2026-03-23Recommended：34
Cabozantinib (Cabometyx) was first approved by the FDA in 2012. It is a non‑specific tyrosine kinase inhibitor that exerts antitumor activity by selectively inhibiting the MET, VEG···【more】
Article source：Captain MedicineRelease date：2026-03-20Recommended：48
On March 26, 2025, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) for the treatment of two patient populations:Adul···【more】
Article source：Captain MedicineRelease date：2026-03-20Recommended：58
Cabozantinib is a small-molecule multi-targeted tyrosine kinase inhibitor developed by Exelixis, Inc. (USA). It was first approved by the FDA in November 2012 for progressive metas···【more】
Article source：Captain MedicineRelease date：2026-03-20Recommended：46
Cabozantinib is a broad‑spectrum multi‑targeted anticancer drug that inhibits at least 9 targets, including MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, and KIT.Side Effects Requiring Im···【more】
Article source：Captain MedicineRelease date：2026-03-20Recommended：37
Lorlatinib is a novel, third-generation, small-molecule dual ALK/ROS1 inhibitor developed by Pfizer Inc., USA.Side Effects of Lorlatinib Requiring Immediate Medical AttentionSeek i···【more】
Article source：Captain MedicineRelease date：2026-03-19Recommended：58
Lorlatinib was first approved in Japan in September 2018, followed by approval from the U.S. Food and Drug Administration (FDA) in November of the same year, and in the European Un···【more】
Article source：Captain MedicineRelease date：2026-03-19Recommended：104
Dabrafenib is a selective BRAF serine-threonine kinase inhibitor that exerts antitumor effects by specifically targeting the BRAF V600E/V600K mutation site. Developed by Novartis P···【more】
Article source：Captain MedicineRelease date：2026-03-19Recommended：51
Dabrafenib is a kinase inhibitor developed by Novartis Pharmaceuticals. It was first approved by the FDA for marketing on May 29, 2013. Dabrafenib inhibits the cell growth of vario···【more】
Article source：Captain MedicineRelease date：2026-03-19Recommended：36
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2252025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2312025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2452025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2242025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2532025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2342025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2162025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
